White House pressure prompts FDA to reopen Moderna flu shot review
TL;DR Summary
The FDA reversed its initial refusal to accept Moderna’s seasonal flu vaccine filing after a White House meeting in which President Trump pressed the agency, with Moderna submitting an amended filing and the FDA agreeing to review it via a Type A meeting. The agency accepted the application for full approval for adults 50–64 and accelerated approval for 65+, with a post‑marketing study to address age-related concerns, and a target decision date of August 5, 2026.
- FDA's reversal on Moderna flu shot bid followed White House pressure Politico
- F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine - The New York Times The New York Times
- FDA reverses course on Moderna flu shot NPR
- U.S. rejection of new mRNA flu vaccine 'sends chills,' epidemiologist says PBS
- Moderna stock surges as FDA reverses course, agrees to review new flu shot Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
9
Time Saved
6 min
vs 7 min read
Condensed
94%
1,340 → 76 words
Want the full story? Read the original article
Read on Politico